Fig. 5: Prespecified exploratory analysis. | Nature Communications

Fig. 5: Prespecified exploratory analysis.

From: Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

Fig. 5

Oncoprint of concomitant mutation in 21 treatment-naïve advanced gastric cancer patients in ITT (A). The association between FAT4 mutation, and clinical benefit from anlotinib plus toripalimab (B). P value, two-sided Fisher exact test for ORR analysis; log-rank test for PFS and OS analysis. Source data are provided as a Source Data file.

Back to article page